Diet, physical activity, and health-related outcomes of endometrial cancer survivors in a behavioral lifestyle program: the Diet and Exercise in Uterine Cancer Survivors (DEUS) parallel randomized controlled pilot trial.


Journal

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
ISSN: 1525-1438
Titre abrégé: Int J Gynecol Cancer
Pays: England
ID NLM: 9111626

Informations de publication

Date de publication:
03 2019
Historique:
received: 21 03 2018
revised: 18 08 2018
accepted: 31 08 2018
pubmed: 7 2 2019
medline: 23 1 2020
entrez: 7 2 2019
Statut: ppublish

Résumé

To explore the effectiveness of a theory-based behavioral lifestyle intervention on health behaviors and quality of life in endometrial cancer survivors.' This was a secondary analysis of a randomized controlled pilot trial conducted in two UK hospitals enrolling disease-free stage I-IVA endometrial cancer survivors. Participants were allocated to an 8-week group-based healthy eating and physical activity intervention or usual care using 1:1 minimization. Participants were followed up at 8 and 24 weeks, with the 8-week assessment being blinded. Diet, physical activity, and quality of life were measured with the Alternative Healthy Eating Index 2010, Stanford 7-Day Physical Activity Recall, and the EORTC Quality of life Questionnaire Core 30, respectively. We analyzed all eligible participants using the intention-to-treat approach in complete cases, adjusting for baseline values, body mass index, and age. We enrolled 60 of the 296 potentially eligible endometrial cancer survivors (May - December 2015). Fifty-four eligible participants were randomized to the intervention (n=29) or usual care (n=31), and 49 had complete follow-up data (n=24 in the intervention and n= 25 in usual care). Intervention adherence was 77%. At 8 weeks, participants in the intervention improved their diet compared to usual care (difference in Alternative Healthy Eating Index 2010 score 7.5 (95% CI: 0.1 to 14.9), P=0.046) but not their physical activity (0.1 metabolic equivalent-h/day 95% CI: (-1.6 to 1.8), P=0.879), or global quality of life score (5.0 (95% CI: -3.4 to 13.3), P=0.236). Global quality of life improved in intervention participants at 24 weeks (difference 8.9 (95% CI: 0.9 to 16.8), P=0.029). No intervention-related adverse events were reported. The potential effectiveness of the intervention appeared promising. A future fully-powered study is needed to confirm these findings. NCT02433080.

Identifiants

pubmed: 30723098
pii: ijgc-2018-000039
doi: 10.1136/ijgc-2018-000039
doi:

Banques de données

ClinicalTrials.gov
['NCT02433080']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

531-540

Subventions

Organisme : Cancer Research UK
ID : 14133
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom

Informations de copyright

© IGCS and ESGO 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: DAK and RJB are volunteers for the charity Weight Concern, which developed the 'Shape-Up' program for the general population.

Auteurs

Dimitrios A Koutoukidis (DA)

Department of Women's Cancer, EGA Institute for Women's Health, University College London, London, UK.
Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.

Rebecca J Beeken (RJ)

Department of Behavioural Science and Health, University College London, London, UK.
Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.

Ranjit Manchanda (R)

Department of Gynaecological Oncology, Barts Health NHS Trust, Royal London Hospital, London, UK.
Barts Cancer Institute, Queen Mary University of London, London, UK.

Matthew Burnell (M)

Department of Women's Cancer, EGA Institute for Women's Health, University College London, London, UK.

Nida Ziauddeen (N)

MRC Human Nutrition Research, Elsie Widdowson Laboratory, University of Cambridge, Cambridge, UK.
Academic Unit of Primary Care and Population Sciences, University of Southampton, Southampton, UK.

Moscho Michalopoulou (M)

Department of Women's Cancer, EGA Institute for Women's Health, University College London, London, UK.
Department of Behavioural Science and Health, University College London, London, UK.

M Tish Knobf (MT)

Department of Women's Cancer, EGA Institute for Women's Health, University College London, London, UK.
Acute Care/Health Systems Division, Yale University School of Nursing, West Haven, Connecticut, USA.

Anne Lanceley (A)

Department of Women's Cancer, EGA Institute for Women's Health, University College London, London, UK a.lanceley@ucl.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH